Inhibitors of DDX3 activity are anti-tumoral in multiple cancer types; however, considering the prevalence of mutant DDX3 and helicase-independent function of DDX3, pharmacological agents that suppress DDX3 expression could have a wider clinical applicability. This evidence concerns the gene DDX3X and cancer.